Ainos (AIMD) Stock Price, News & Analysis

Company Overview

Ainos, Inc. (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format. AI‐401 is engineered to target airway inflammation in conditions such as cystic fibrosis and other chronic respiratory diseases. In preclinical studies, the formulation demonstrated favorable pulmonary deposition and sustained release, and it has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of cystic fibrosis.

In addition to AI‐401, Ainos is exploring the application of its dry powder inhalation technology for other anti‐inflammatory and anti‐infective agents, with the goal of expanding its pipeline into multiple respiratory indications. The company collaborates with contract development and manufacturing organizations (CDMOs) to advance product candidates through formulation optimization, toxicology assessments and early clinical trials.

Founded in the United States, Ainos is headquartered in Philadelphia and serves patients and healthcare providers primarily in North America and Europe. The company’s management team comprises executives with extensive experience in respiratory drug development, regulatory affairs and commercial strategy. Ainos aims to leverage its inhalation platform to bring novel pulmonary therapies to market and address unmet medical needs in chronic lung disease.

Key Stats

• Today's Range: $1.80 to $1.90
• 50-Day Range: $1.50 to $3.16
• 52-Week Range: $1.26 to $4.50
• Volume: 8,262 shs
• Average Volume: 89,414 shs
• Market Capitalization: $15.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Ainos Stock Analysis - MarketRank™

Ainos scored higher than 18% of companies evaluated by MarketBeat, and ranked 802nd out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Ainos has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Ainos has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Ainos is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ainos is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ainos has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.24% of the float of Ainos has been sold short.

Short Interest Ratio / Days to Cover

Ainos has a short interest ratio ("days to cover") of 0.28, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ainos has recently decreased by 79.80%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ainos does not currently pay a dividend.

Dividend Growth

Ainos does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Ainos this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for AIMD on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Ainos insiders have sold 2,152.90% more of their company's stock than they have bought. Specifically, they have bought $15,946.00 in company stock and sold $359,247.00 in company stock.

Percentage Held by Insiders

9.79% of the stock of Ainos is held by insiders.

Percentage Held by Institutions

Ainos has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/13/2026
• Today: 6/25/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AIMD
• Previous Symbol: NASDAQ:AIMD
• CIK: 1014763
• Web: www.ainos.com
• Phone: 858-869-2986
• Fax: 806-376-9301
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.77 million
• Net Margins: -11,912.10%
• Pretax Margin: -77,466.66%
• Return on Equity: -160.55%
• Return on Assets: -62.29%

Debt

• Debt-to-Equity Ratio: 1.58
• Current Ratio: 0.55
• Quick Ratio: 0.50

Sales & Book Value

• Annual Sales: $120 thousand
• Price / Sales: 127.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.29 per share
• Price / Book: 1.40

Miscellaneous

• Outstanding Shares: 8,520,000
• Free Float: 7,690,000
• Market Cap: $15.34 million
• Optionable: Not Optionable
• Beta: 2.41